ValiRx PLC New European patent allowance for VAL301 (4617H)
01 Agosto 2019 - 8:00AM
UK Regulatory
TIDMVAL
RNS Number : 4617H
ValiRx PLC
01 August 2019
VALIRX PLC
("ValiRx", the "Company" or the "Group")
EUROPEAN PATENT NOTICE OF ALLOWANCE FOR THERAPEUTIC COMPOUND,
VAL301
London, UK., 01 August 2019: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company, announces that the European Patent
Office ("EPO") has issued a Patent Notice of Allowance for ValiRx's
pre-clinical therapeutic compound, VAL301, subject to payment of
the relevant fees.
The VAL301 compound is derived from ValiRx's lead compound,
VAL201 and its potential therapeutic approach is based on the same
mode of action. VAL301 is currently in late-stage pre-clinical
development (announced 17/07/18) as a non-invasive, effective
treatment for the non-cancerous, but hugely debilitating
gynaecological condition, endometriosis, which is characterised by
endometrial-like tissue found outside of the uterine cavity. The
condition represents one of the major causes of female
infertility.
The compound has been developed for the treatment of
hormone-induced, non-oncological abnormal growth and cell
proliferation conditions. These include indications for
endometriosis and benign prostatic hyperplasia, for both of which
there is substantial global unmet medical need.
This latest European patent allowance provides additional
protection for ValiRx and the allowance in another of the world's
populous regions follows on from ValiRx's earlier receipt last year
of a US Patent Grant (announced 17/07/18) and the more recent
Patent Allowances covering China and the Russian Federation
(announced 31/01/19).
Dr Satu Vainikka, CEO of ValiRx plc, commented: "This is
excellent news and I am delighted that the patent portfolio for our
lead compounds continues to strengthen, add value and receive
further endorsement.
The current list of Patent Grants and Allowances pertaining to
the compounds, VAL301 and VAL201, are as follows:
VAL 301 - endometriosis
Country/Region Patent number Date filed Granted/Allowed
Europe EU 12840836.6 1 November 2012 Allowed
---------------- ---------------- ----------------
United States US 10,023,612 1 November 2012 Granted
---------------- ---------------- ----------------
China ZL2012800657582 1 November 2012 Granted
---------------- ---------------- ----------------
Russia RU 2684315 1 November 2012 Granted
---------------- ---------------- ----------------
United Kingdom GB 2496135 1 November 2011 Granted
---------------- ---------------- ----------------
VAL 201 - prostate cancer and metastatic prostate cancer
Country Patent number Date filed Granted/Allowed
United States US 14/888,214 30 April 2014 Allowed
-------------- -------------- ----------------
United States US 9,919,023 14 March 2008 Granted
-------------- -------------- ----------------
Europe EP 2139917 14 March 2008 Granted
-------------- -------------- ----------------
Japan JP 5998161 14 March 2008 Granted
-------------- -------------- ----------------
Japan JP 6456922 30 April 2014 Granted
-------------- -------------- ----------------
Australia AU 2008228274 14 March 2008 Granted
-------------- -------------- ----------------
Japan JP 6545122 14 March 2008 Granted
-------------- -------------- ----------------
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879 458
364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880
Adviser)
Liam Murray / Jo Turner / Ludovico
Lazzaretti
SVS Securities PLC (Joint Broker) Tel: +44 (0) 20 3700 0093
Elliot Hance
Novum Securities Limited (Joint Broker) Tel: +44 (0) 20 7399 9400
Colin Rowbury
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCRBMRTMBAJBTL
(END) Dow Jones Newswires
August 01, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Apr 2023 a Apr 2024
